Open AccessRecipient Interleukin-28B Rs12979860 C/T Polymorphism and Acute Cellular Rejection After Liver Transplantation
Author(s) -
Davide Bitetto,
Carlo Fabris,
Edmondo Falleti,
Ezio Fornasiere,
Claudio Avellini,
Sara Cmet,
Annarosa Cussigh,
Elisabetta Fontanini,
Mario Pirisi,
Stefano Ginanni Corradini,
Manuela Merli,
Antonio Molinaro,
Pierluigi Toniutto
Publication year - 2012
Publication title -
transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.45
H-Index - 204
eISSN - 1534-6080
pISSN - 0041-1337
DOI - 10.1097/tp.0b013e31824df7f3
Subject(s) - interleukin 28b , liver transplantation , medicine , genotype , gastroenterology , hepatitis c virus , hepatitis c , transplantation , odds ratio , allele , immunology , biology , virus , ribavirin , gene , biochemistry
Interleukin-28 (IL-28B) rs12979860 C/T polymorphism is known to predict the outcome of antiviral therapy in hepatitis C. In addition to its interferon-like and antiviral functions, IL-28B possesses the ability to modulate CD8 T cells function. This study aimed to investigate whether recipient IL-28B polymorphism may have a role in predicting the occurrence of acute cellular rejection (ACR) after liver transplantation (LT).